- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Marapharm Comments on CSA Notice on US Cannabis Interest
Marapharm Ventures issued a comment on the staff notice sent by the CSA regarding cannabis operators with interests in the US while listed in Canada.
Marapharm Ventures (CSE:MDM; OTXQX:MRPHF) issued a comment on the staff notice sent by the Canadian Securities Administrators (CSA) regarding cannabis operators with interests in the US while listed in Canada.
As quoted in the press release:
“Marapharm’s management is pleased with the content of the notice and is encouraged that regulators are taking a disclosure-forward approach to what is a complex issue, especially given the differing legal status of cannabis from State to State, as well as its status as a scheduled narcotic from the Federal Governments vantage point. Marapharm feels that the US Federal Government does not intend to meaningfully alter the way that existing cannabis business is conducted within legal US jurisdictions and believe the absence of meaningful enforcement in those legal states that have opted for recreational and medical legalization is proof of this. Marapharm intends to continue to pursue opportunities that may arise in the U.S. and encourages investors to take comfort from recent developments and successes,” states Linda Sampson, Marapharm’s CEO.
Click here to read the full press release.
Source: www.newswire.ca
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.